Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines

Development of noninvasive treatments for erythroplasia of Queyrat, a carcinoma in situ, is expected. This case suggests topical imiquimod might be a candidate with regimens consisting of much longer duration of the treatment than for genital warts and the maintenance phase of the treatment course t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoyama, Maiko, Egawa, Gyohei, Makino, Takamitsu, Egawa, Kiyofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452465/
https://www.ncbi.nlm.nih.gov/pubmed/30997072
http://dx.doi.org/10.1002/ccr3.2076
_version_ 1783409294250606592
author Yokoyama, Maiko
Egawa, Gyohei
Makino, Takamitsu
Egawa, Kiyofumi
author_facet Yokoyama, Maiko
Egawa, Gyohei
Makino, Takamitsu
Egawa, Kiyofumi
author_sort Yokoyama, Maiko
collection PubMed
description Development of noninvasive treatments for erythroplasia of Queyrat, a carcinoma in situ, is expected. This case suggests topical imiquimod might be a candidate with regimens consisting of much longer duration of the treatment than for genital warts and the maintenance phase of the treatment course to prevent the relapse.
format Online
Article
Text
id pubmed-6452465
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64524652019-04-17 Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines Yokoyama, Maiko Egawa, Gyohei Makino, Takamitsu Egawa, Kiyofumi Clin Case Rep Case Reports Development of noninvasive treatments for erythroplasia of Queyrat, a carcinoma in situ, is expected. This case suggests topical imiquimod might be a candidate with regimens consisting of much longer duration of the treatment than for genital warts and the maintenance phase of the treatment course to prevent the relapse. John Wiley and Sons Inc. 2019-02-27 /pmc/articles/PMC6452465/ /pubmed/30997072 http://dx.doi.org/10.1002/ccr3.2076 Text en © 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Yokoyama, Maiko
Egawa, Gyohei
Makino, Takamitsu
Egawa, Kiyofumi
Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines
title Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines
title_full Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines
title_fullStr Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines
title_full_unstemmed Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines
title_short Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines
title_sort erythroplasia of queyrat treated with imiquimod 5% cream: the necessity of regimen guidelines
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452465/
https://www.ncbi.nlm.nih.gov/pubmed/30997072
http://dx.doi.org/10.1002/ccr3.2076
work_keys_str_mv AT yokoyamamaiko erythroplasiaofqueyrattreatedwithimiquimod5creamthenecessityofregimenguidelines
AT egawagyohei erythroplasiaofqueyrattreatedwithimiquimod5creamthenecessityofregimenguidelines
AT makinotakamitsu erythroplasiaofqueyrattreatedwithimiquimod5creamthenecessityofregimenguidelines
AT egawakiyofumi erythroplasiaofqueyrattreatedwithimiquimod5creamthenecessityofregimenguidelines

Ejemplares similares